Skip to content
10-K

Annual Report

Climb Bio, Inc. CLYM

0001193125-26-092546

← back to feed
Filed
Mar 5, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 27, 2026 47.77M sh
Shares Diluted FY 2025 · Dec 31, 2025 67.81M sh
Shares Diluted FY 2025 · Dec 31, 2024 48.16M sh
Capex FY 2025 · Dec 31, 2025 $186K
Capex FY 2025 · Dec 31, 2024 $0
Operating Cash Flow FY 2025 · Dec 31, 2025 −$54.36M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$15.56M
Cash And Equivalents FY 2025 · Dec 31, 2025 $35.69M
Cash And Equivalents FY 2025 · Dec 31, 2024 $87.23M
Stockholders Equity FY 2025 · Dec 31, 2025 $160.48M
Stockholders Equity FY 2025 · Dec 31, 2024 $211.88M
Stockholders Equity FY 2025 · Dec 31, 2023 $107.6M
Current Liabilities FY 2025 · Dec 31, 2025 $6.98M
Current Liabilities FY 2025 · Dec 31, 2024 $4.93M
Total Liabilities FY 2025 · Dec 31, 2025 $7.27M
Total Liabilities FY 2025 · Dec 31, 2024 $5.31M
Current Assets FY 2025 · Dec 31, 2025 $105.85M
Current Assets FY 2025 · Dec 31, 2024 $154.87M
Total Assets FY 2025 · Dec 31, 2025 $167.74M
Total Assets FY 2025 · Dec 31, 2024 $217.19M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.88
Eps Diluted FY 2025 · Dec 31, 2024 −$1.53
Eps Basic FY 2025 · Dec 31, 2025 −$0.88
Eps Basic FY 2025 · Dec 31, 2024 −$1.53
Sga Expense FY 2025 · Dec 31, 2025 $21.17M
Sga Expense FY 2025 · Dec 31, 2024 $16.03M
Rd Expense FY 2025 · Dec 31, 2025 $46.71M
Rd Expense restated FY 2025 · Dec 31, 2024 $14.34M
Net Income FY 2025 · Dec 31, 2025 −$59.85M
Net Income FY 2025 · Dec 31, 2024 −$73.9M
Operating Income FY 2025 · Dec 31, 2025 −$67.88M
Operating Income FY 2025 · Dec 31, 2024 −$82.02M